President, Chief Executive
Arrowhead Pharmaceuticals
Anzalone was named president and chief executive of Arrowhead in 2007. Arrowhead develops drugs using an RNA platform that silences genes that cause cancers or other diseases. After its most promising drug failed to win FDA clearance in 2016, Anzalone retooled the company’s platform. Then he inked a series of licensing and drug development deals with major pharmaceutical companies, bringing in much-needed revenue. In February, Arrowhead announced the closing of a licensing deal with Cambridge, Massachusetts-based Sarepta Therapeutics in which Sarepta has the potential to pay Arrowhead nearly $1.4 billion ($825 million of that upfront) for the right to collaborate on the development of most of Arrowhead’s drug platform.
YEARS ON LA500: 6
